RO-7293583

N/A

Report date: 2026/03/19 17:22:59

Base Information

Drug NameRO-7293583

Drug Alias NameRO-7293583

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-TYRP1Anti-CD3

TargetsTyrosinase-related protein 1T cell surface glycoprotein CD3

Therapy Area/IndicationsUveal melanomaSkin MelanomaMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[6]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd

Inactive CompaniesN/A

Active IndicationsUveal melanomaSkin MelanomaMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A